Intracoronary Abciximab reduces events in diabetics during PPCI

abciximabDiabetic patients have an increased risk of future cardiovascular events after an ST elevation MI. Administration of an intracoronary abciximab bolus during primary PCI could be beneficial for this high risk subgroup of patients.

 

This study reports one year clinical outcomes and CMR imaging of patients randomized to intracoronary vs. intravenous abciximab during primary PCI. Primary end point was a composite of death or re-infarction.

 

Of 2,470 patients included in this study, 473 (19%) had diabetes and 1,997 (81%) did not.

 

At one year, primary end point was significantly reduced in diabetic patients receiving intracoronary abciximab compared to those receiving an intravenous bolus (9.2% vs. 17.6%; HR: 0.49; CI 95%: 0.28 to 0.83; p=0.009).

 

The intracoronary abciximab bolus did not reduce events in non-diabetics (7.4% vs. 7.5%; HR: 0.95; CI 95%: 0.68 to 1.33; p=0.77).

 

In diabetic patients, intracoronary abciximab reduced the risk of death (5.8% vs. 11.2%; HR: 0.51; CI 95%: 0.26 to 0.98; p=0.043) and definite/probable thrombosis (1.3% vs. 4.8%; HR: 0.27; CI 95%: 0.08 to 0.98; p=0.046) compared to intravenous abciximab.

 

The savaged myocardium index by CMR saw a significant increase only in diabetic patients randomized to intracoronary abciximab.

 

Conclusion

Intracoronary abciximab bolus administration reduces events in diabetic STEMI patients undergoing primary PCI.

 

Original Title: 1-Year Outcomes with Intracoronary Abciximab in Diabetic Patients Undergoing Primary Percutaneous Coronary Intervention.

Reference: Raffaele Piccolo et al. J Am Coll Cardiol. 2016;68(7):727-738.

 

We value your opinion. You are more than welcome to leave your comments, thoughts, questions or suggestions here below.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...